Nano Dimension's Risky Bet on AI Health Ignites Fierce Shareholder Revolt

TORONTO, ON – June 15, 2026 – Nano Dimension, a company that built its name and raised nearly a billion dollars in capital on the promise of revolutionizing 3D printing, sent shockwaves through the market today with a dramatic strategic pivot. The company announced a non-binding term sheet to merge with Infinite Epigenetics, aiming to create a new, publicly traded entity focused on AI-powered health and diagnostics. The reaction was not what the board likely hoped for. The company’s stock (NASDAQ: NNDM) plummeted 15% on the news, and a prominent activist shareholder has already declared war.

Murchinson Ltd., an alternative asset management firm holding a significant 7.4% stake in Nano Dimension, immediately issued a scathing public rebuke, labeling the proposed transaction “deeply flawed” and “value-destructive.” The move signals an escalating battle for the soul of Nano Dimension, pitting a board seeking radical transformation against investors who feel the company is recklessly abandoning its core identity and fiduciary duty.

A 'SPAC-Like' Deal Without an Exit

Murchinson’s sharpest criticism centers on the very structure of the deal. In a pointed public letter, the firm questioned Nano Dimension's leadership: “How is this transaction meaningfully different from a SPAC?” The comparison is damning. Special Purpose Acquisition Companies (SPACs) have a checkered reputation for over-promising and under-delivering. Murchinson argues that Nano Dimension is effectively turning itself into a cash shell to acquire a private company in an unrelated field—a classic SPAC maneuver.

However, the activist investor notes one critical, and unfavorable, difference. In traditional SPAC transactions, shareholders who dislike the proposed merger have the right to redeem their shares for cash. According to Murchinson, this fundamental protection appears to be absent from the Infinite Epigenetics deal, leaving dissenting shareholders trapped in a venture they never signed up for. This lack of an exit ramp is compounded by deal terms that Murchinson describes as “particularly prohibitive.” The term sheet includes a termination fee that could cost Nano Dimension up to $10 million if its own shareholders reject the transaction, alongside “specific performance” and “best efforts” clauses that could legally compel the company to push the deal forward. “Why did the Board agree to a termination fee that appears particularly prohibitive to Nano?” Murchinson asked, highlighting a provision that seemingly penalizes shareholders for exercising their oversight.

From Printers to Patients: A Crisis of Identity

For years, Nano Dimension’s pitch to investors was clear and consistent: a “razor and blades” strategy centered on its proprietary 3D printers for additively manufactured electronics. Investors poured capital into the company based on this vision. The abrupt shift into the highly complex and regulated field of epigenetics has left many, including Murchinson, questioning the board’s mandate.

CEO Dave Stehlin has defended the company's new direction by citing the need for “strategic flexibility.” Yet, Murchinson argues this flexibility was never disclosed to the investors who funded the company’s war chest. “When Nano raised capital through stock issuances, investors were presented with a business model centered on a ‘razor and blades’ strategy,” the firm stated, noting that even the most recent annual report gives no hint of a pivot into healthcare. This raises a fundamental question at the heart of this conflict: Does a board have the right to completely redefine a company’s mission without explicit shareholder consent, especially when venturing into a field where it appears to have no institutional expertise?

Murchinson directly challenged the board on this point, asking, “What relevant qualifications do the Board members have to evaluate a business operating in epigenetics?” The question implies that the board is acting outside its circle of competence, using shareholder funds to gamble on a trendy sector rather than executing a focused, disciplined strategy.

Déjà Vu in the Boardroom

Adding a layer of historical controversy to the dispute, Murchinson drew a direct and uncomfortable line from the current proposal to a past corporate failure. The firm highlighted that a key advisor to Infinite Epigenetics is retired General Michael X. Garrett. Shareholders with long memories will, as Murchinson pointedly notes, “recall that Gen. Garrett served on Nano’s Board when it unanimously approved the Desktop Metal acquisition.”

That deal is remembered by critics as a debacle that destroyed hundreds of millions of dollars in capital. The connection, whether coincidental or not, paints a troubling picture. Murchinson’s message is clear: a figure associated with a major past strategic failure is now involved in a new, equally speculative venture. “We question whether the Board expects shareholders to ignore this connection,” the firm declared, suggesting a pattern of poor judgment and a failure to learn from costly mistakes.

This history fuels Murchinson’s central accusation: that the board’s actions are “entrenchment-driven,” designed more to preserve their positions than to create shareholder value. The swift 15% drop in stock price following the announcement is being wielded by the activist as a real-time referendum on the board’s decision-making. As far as Murchinson is concerned, the market has already rendered its verdict. The firm is now demanding that the board, which allegedly refused to take shareholder questions on its investor call, provide full and direct answers regarding a transaction that could permanently alter the future of the company.